RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Tuberous Sclerosis Complex-associated Refractory Seizures

Conditions

Tuberous Sclerosis Complex-associated Refractory Seizures

Trial Timeline

Apr 29, 2013 → Oct 25, 2017

NCT ID

NCT01713946

About RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)

RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) is a phase 3 stage product being developed by Novartis for Tuberous Sclerosis Complex-associated Refractory Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT01713946. Target conditions include Tuberous Sclerosis Complex-associated Refractory Seizures.

What happened to similar drugs?

1 of 7 similar drugs in Tuberous Sclerosis Complex-associated Refractory Seizures were approved

Approved (1) Terminated (1) Active (5)

✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved

🔄Everolimus (RAD001) + Everolimus PlaceboNovartisPhase 3

🔄Everolimus + PlaceboNovartisPhase 3

🔄everolimusNovartisPhase 3

❌GWP42003-PJazz PharmaceuticalsPhase 3

🔄GWP42003-PJazz PharmaceuticalsPhase 3

🔄GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01713946	Phase 3	Completed	Apr 29, 2013	Oct 25, 2017	Tuberous Sclerosis Complex-associated Refractory Seizures

Competing Products

13 competing products in Tuberous Sclerosis Complex-associated Refractory Seizures

See all competitors

Product	Company	Stage	Hype Score
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	40
Everolimus + Placebo	Novartis	Phase 3	40
RAD001	Novartis	Phase 1/2	32
Placebo + Everolimus (RAD001)	Novartis	Phase 2	31
RAD001 + Placebo	Novartis	Phase 2	35
Everolimus	Novartis	Phase 1/2	32
everolimus (RAD001)	Novartis	Phase 1/2	32
everolimus	Novartis	Phase 3	44
sirolimus	Pfizer	Phase 2	31
GWP42003-P	Jazz Pharmaceuticals	Phase 3	29
GWP42003-P	Jazz Pharmaceuticals	Phase 3	37
GWP42003-P + Placebo	Jazz Pharmaceuticals	Phase 3	37
Cannabidiol Oral Solution [Epidiolex]	Jazz Pharmaceuticals	Approved	44